Literature DB >> 25935942

The role of peri-operative use of alpha-blocker in preventing lower urinary tract symptoms in high risk patients of urinary retention undergoing inguinal hernia repair in males above 50 years.

Manoj K Shaw, Hirak Pahari.   

Abstract

Prevalence of lower urinary tract symptoms (LUTS) and groin hernia increase with rising age. Straining in itself is an important aetiology of inguinal hernia. Posthernioplasty retention of urine is one of the most significant complications. The aims of this study are to know the prevalence of signifi- cant LUTS in men > 50 years (n = 200) undergoing inguinal hernia surgery, to identify the high-risk patients for posthernioplasty urinary retention and to assess the role of peri-operative use of alpha- blocker in reducing the incidence of postoperative urinary retention in these patients. This study was performed at RKMSP Hospital, Kolkata from August 2005 to January 2008. All findings were docu- mented. Prevalence of significant LUTS above 50 years undergoing inguinal hernioplasty was found to be 48% (96 out of 200). Out of 96 patients who had International Prostate Symptoms Score>7, 48 patients had maximal urine flow (Qmax) < 10 ml/second and postvoid residual urine > 100 ml, 48 patients belonged to high risk group for postoperative retention of urine. Incidence of postoperative retention of urine among high risk group among tamsulosin users was only 3(12.5%) out of 24 patients and among tamsulosin non-users was 10(41.6%) out of another 24 patients. Therefore, we concluded that among male patients > 50 years of age (undergoing groin hernia surgery) prevalence of significant LUTS increases per decade. We also concluded that tamsulosin is important for alleviation of LUTS and is quite effective for prevention of postoperative retention of urine and helpful for early discharge of patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25935942

Source DB:  PubMed          Journal:  J Indian Med Assoc        ISSN: 0019-5847


  6 in total

1.  Identifying patients at risk for urinary retention following inguinal herniorrhaphy: a single institution study.

Authors:  B R Hall; P R Armijo; B Grams; D Lomelin; D Oleynikov
Journal:  Hernia       Date:  2018-09-25       Impact factor: 4.739

2.  Risk Factors for Postoperative Urinary Retention After Endoscopic Hernia Repair: Age and Unilateral Operation make the Difference.

Authors:  S Di Natale; J Slieker; S Soppe; U Bieri; A Keerl; A Nocito
Journal:  World J Surg       Date:  2021-08-23       Impact factor: 3.352

3.  RETention of urine After INguinal hernia Elective Repair (RETAINER study I and II).

Authors:  Stefanie M Croghan; Christina A Fleming; Helen M Mohan; Deena Harji; Jarlath C Bolger; Jessie A Elliott; Michael Boland; Peter E Lonergan; Patrick Dillon; David M Quinlan; Des C Winter
Journal:  Int J Surg Protoc       Date:  2021-04-23

4.  Lower urinary tract symptoms-Benign prostatic hyperplasia may increase the risk of subsequent inguinal hernia in a Taiwanese population: A nationwide population-Based cohort study.

Authors:  Yi-Hsuan Wu; Yung-Shun Juan; Jung-Tsung Shen; Hsun-Shuan Wang; Jhen-Hao Jhan; Yung-Chin Lee; Jiun-Hung Geng
Journal:  PLoS One       Date:  2020-06-08       Impact factor: 3.240

5.  Randomised, quadruple blinded, placebo controlled, multicentre trial investigating prophylactic tamsulosin in prevention of postoperative urinary retention in men after endoscopic total extraperitoneal inguinal hernia repair (STOP-POUR trial): a study protocol.

Authors:  Uwe Bieri; Juliette Slieker; Lukas John Hefermehl; Sebastian Soppe; Gerfried Teufelberger; Regula Tedaldi; Nicole Graf; Marco Bieri; Antonio Nocito
Journal:  BMJ Open       Date:  2021-12-07       Impact factor: 2.692

6.  Medical and non-medical interventions for post-operative urinary retention prevention: network meta-analysis and risk-benefit analysis.

Authors:  Pokket Sirisreetreerux; Rujira Wattanayingcharoenchai; Sasivimol Rattanasiri; Oraluck Pattanaprateep; Pawin Numthavaj; Ammarin Thakkinstian
Journal:  Ther Adv Urol       Date:  2021-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.